Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) by Year
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. sales ($M) ($M)
Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib): $534M in FY2025, up 107.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 534 | +107.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 257 | +289.4% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 66 | – | Form 10-K (filed 2026-02-11) ↗ |
Breakdown
What makes up RYBREVANT / LAZCLUZE (amivantamab / lazertinib)
Cite this data
StockData. (2026). Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) ($M), annual FY2023–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-rybrevant-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.